Yüklüyor......
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are currently used as second-line therapy for treatment of patients with type 2 diabetes mellitus (T2DM). Based on the results from dedicated cardiovascular outcome trials (CVOTs), current guidelines suggest the use of SGLT-2 inhibitors for patient...
Kaydedildi:
| Yayımlandı: | Diabetes Metab Syndr Obes |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899064/ https://ncbi.nlm.nih.gov/pubmed/31819580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S190356 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|